Gossamer Bio Inc.

0.99
-0.00 (-0.43%)
At close: Apr 02, 2025, 3:59 PM
0.98
-1.31%
Pre-market: Apr 03, 2025, 07:00 AM EDT

Company Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States.

The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds.

The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.

Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio Inc.
Gossamer Bio Inc. logo
Country United States
IPO Date Feb 8, 2019
Industry Biotechnology
Sector Healthcare
Employees 144
CEO Faheem Hasnain

Contact Details

Address:
3013 Science Park Road
San Diego, California
United States
Website https://www.gossamerbio.com

Stock Details

Ticker Symbol GOSS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001728117
CUSIP Number 38341P102
ISIN Number US38341P1021
Employer ID 47-5461709
SIC Code 2834

Key Executives

Name Position
Faheem Hasnain Co-Founder, Chief Executive Officer, President & Chairman
Bryan Giraudo Chief Operating Officer & Chief Financial Officer
Caryn L. Peterson Executive Vice President of Regulatory Affairs
Christian Waage J.D. Executive Vice President of Technical Operations & Administration
Deanna Weber Senior Vice President of Human Resources
Dr. Richard Aranda M.D. Chief Medical Officer
Jeanine Anthony Senior Vice President of Marketing
Jeff Boerneke General Counsel & Secretary
Matt Cravets Senior Vice President of Biometrics
Robert P. Smith Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 13, 2025 S-8 Filing
Mar 13, 2025 8-K Current Report
Mar 13, 2025 10-K Annual Report
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Feb 19, 2025 8-K Current Report